clinical trial · NCT06142188
Relmacabtagene Autoleucel in Hematologic Malignancies
Shanghai Ming Ju Biotechnology Co., Ltd.·—·not yet recruiting·n = 150
Lymphoma, B-CellLarge B-cell LymphomaFollicular LymphomaRelmacabtagene Autoleucel
brief summary
To evaluate the efficacy and safety of Relmacabtagene Autoleucel in the treatment of adult patients with hematologic malignancies in real-world
started
Dec 28, 2023
primary completion
Dec 31, 2038
completion
Dec 31, 2038
last updated
Nov 21, 2023
detailed description
The purpose of this study is to observationally evaluate the efficacy and safety data of Relmacabtagene Autoleucel for the treatment of patients with hematologic malignancies for up to 15 years after infusion. The treating physician will determine the most appropriate diagnostic and therapeutic regimen for the patient based on clinical practice. No therapeutic intervention will be administered to patients in this study.
official title
A Real-world Study for the Treatment of Hematologic Malignancies With Relmacabtagene Autoleucel
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol